Geva, M., Goldberg, Y. P., Leitner, M. L., Chen, K., Feng, W., Emek, N. G., . . . Hayden, M. R. Pridopidine treatment benefits in definite, probable, and early (<18mo onset) subjects with ALS in the HEALEY ALS Platform Trial. Elsevier.
Chicago Style (17th ed.) CitationGeva, Michal, et al. Pridopidine Treatment Benefits in Definite, Probable, and Early (<18mo Onset) Subjects with ALS in the HEALEY ALS Platform Trial. Elsevier.
MLA (9th ed.) CitationGeva, Michal, et al. Pridopidine Treatment Benefits in Definite, Probable, and Early (<18mo Onset) Subjects with ALS in the HEALEY ALS Platform Trial. Elsevier.
Warning: These citations may not always be 100% accurate.